Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (331-340 of 446) with videos related to

Pageof 45
Sort By:
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood Cancer Journal|December 10, 2023
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myelomaCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Pageof 45

Showing results (331-340 of 446) with videos related to

Sort By:
Pageof 45
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood Cancer Journal|December 10, 2023
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myelomaCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Pageof 45